@article{TLCR30588,
author = {Editorial Office},
title = {The first attempt worldwide to test PD-1 antibody on multiple “Stage 0” lung cancer},
journal = {Translational Lung Cancer Research},
volume = {8},
number = {4},
year = {2019},
keywords = {},
abstract = {The editorial board recently noticed that a Chinese research team had launched a phase II, prospective, Simon’s two-stage design study which evaluates the efficacy and safety of PD-1 antibody Sintilimab on unresectable early-stage multiple primary lung cancer (MPLC) with ground-glass density (CCTC-1901, NCT04026841) (Figure 1). This is the first documented study worldwide to test PD-1 antibody on “Stage 0” lung cancer, on July 24, 2019.},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/30588}
}